BusinessSummit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual MeetingBy Nasdaq OMXMar 28, 2018, 11:00 AM UTC
BusinessSummit Highlights Scientific Rigour of its PhaseOut DMD Clinical Trial at MDA Clinical ConferenceBy Nasdaq OMXMar 14, 2018, 11:00 AM UTC
BusinessSummit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional GroupBy Nasdaq OMXMar 7, 2018, 12:02 PM UTC
BusinessEzutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical TrialBy Nasdaq OMXJan 25, 2018, 12:01 PM UTC
BusinessSummit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients With DMD in PhaseOut DMD Clinical TrialBy Nasdaq OMXNov 20, 2017, 12:00 PM UTC
BusinessSummit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International ConferenceBy Nasdaq OMXNov 9, 2017, 12:01 PM UTC
BusinessSummit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular DystrophyBy Nasdaq OMXSep 25, 2017, 11:00 AM UTC
